SCHEMBL25340620

SCHEMBL25340620

COc1cccc(F)c1-c1csc(C(=O)O)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
MAP4K1 Q92918 2/20 0.41
CTSA P10619 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
EIF4E P06730 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25956911 0.88 CYP3A4 (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL167409 0.78 HPGDS (0.60) EIF4EHPGDSECE1MEN1KMT2A
SCHEMBL25340012 0.77 KDM4E (0.45) MAP4K1CTSACA12CA1CA2
SCHEMBL3536356 0.76 ALDH1A1 (0.55) CTSAHPGDSECE1PIM1PIM3
SCHEMBL30448183 0.76 ALDH1A1 (0.55) CTSAHPGDSECE1PIM1PIM3
SCHEMBL31250000 0.74 MAP4K1 (0.44) MAP4K1CTSACA12CA1CA2
SCHEMBL31401007 0.73 MPL (0.58) EIF4EMEN1KMT2A
SCHEMBL31401012 0.72 HSD17B10 (0.40) ECE1PIM1PIM3MEN1KMT2A
SCHEMBL14742925 0.71 KMT2A (0.62) MEN1KMT2A
SCHEMBL28048533 0.70 ALDH1A1 (0.63) EIF4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122174-A1 Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) 2025-04-17 US disclosed
CN-119365192-A Heteroaryl compounds as HPK1 inhibitors and methods of use thereof 深圳市原力深湾创新药有限公司 2025-01-24 CN disclosed
EP-4463150-A1 HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME Shenzhen Ionova Life Science Co., Ltd. (CN) 2024-11-20 EP disclosed
WO-2023137406-A1 HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) 2023-07-20 WO disclosed
WO-2023137406-A1 HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122174-A1 Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same SGK1, HYPK, PCK1 HDAC3 231/4885HDAC4 832/4885HDAC1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.